symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
VKTX,10.72,0.497061,1867900,1072310880,0,3.44-25.72,-0.04,"Viking Therapeutics, Inc.",USD,0001607678,US92686J1060,92686J106,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.vikingtherapeutics.com,"Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.",Dr. Brian  Lian Ph.D.,Healthcare,US,22,858 704 4660,9920 Pacific Heights Boulevard,San Diego,CA,92121,4.19675,4.37325,https://financialmodelingprep.com/image-stock/VKTX.png,2015-04-28,False,False,True,False,False
